Swing Trade Ideas

🏃🚀✅  HWH high $7.43 on 9/2, up over 470% 

🏃🚀✅  OPAD high $6.31, up over 530%

🏃🚀✅  TLRY high $1.64, up over  48% 

🏃🚀✅  OPEN high $5.87, up over 193% 

🏃🚀✅  CAPS high $2.14, up over 52%

🏃🚀✅  APM high 3.69, up over 195% 

🏃🚀✅ KIDZ high premarket 1.83 from low 1.30, 40%

✅ CAPS potential entry: $1.15 – $1.25  

🎯 Potential PT1: $1.40 – $1.80, 🎯 PT2: $2.00 – $2.50, 🎯 PT3: $2.60 – $3.30  

🚫 Potential Stop: Below $1.00 or 2%–5% or daily max risk per trade
Another rinse and repeat from recent high above 2, back to support, small float, recently announced closing of its acquisition of Caroline Stone Products and expanding its Southeast presence, boosting revenue by $11 Million,  recently secured $3m for strategic acquisition, company focuses on developing peptide-based therapies for cardiovascular conditions, consensus buy rating, Joseph Gunnar analyst price target $6, DOES have active mixed shelf recently filed, be mindful on next big spike 

✅ SONN potential entry: $3.20 – $3.30  

🎯 Potential PT1: $3.60 – $3.90, 🎯 PT2: $4.00 – $4.50, 🎯 PT3: $4.60 – $5.40  

🚫 Potential Stop: Below $3.00 or 2%–5% or daily max risk per trade  

 Back to consolidation from recent high above $19 on merger news, recently announced expansion of its phase 1b/2a study evaluating combination of SON-1010 with Genetech's Atezolizumab in patient with Platinum-resistance ovarian cancer, recently announced merging with Rorschach I to create Hyperliquid strategies (HSI), a new public company focused on holding and managing HYPE, a top cryptocurrency, merger expected to close 2nd half of 2025, company focuses on developing targeted immuno-oncology therapies through its proprietary FHAB (Fully human albumin-binding) platform, Chardan Capital price target $20, does have mixed shelf, be mindful on next spike 

✅ IMUX potential entry: $0.82 – $0.87  

🎯 Potential PT1: $1.10 – $1.50, 🎯 PT2: $1.60 – $1.85, 🎯 PT3: $2.00 – $2.60  

🚫 Potential Stop: Below $0.55 or 2%–5% or daily max risk per trade
Another rinse and repeat, back to near 52wk low from recent high, recently announced positive clinical data from phase 2 of vidofludimus calcium for multiple sclerosis, Executive chairman recently bought 20,000 shares, CEO and Director Daniel Vitt bought 15,000 shares, CFO  bought 45,000, D. Boral Capital price target $10, B. Riley Securities price target $6, HC Wainwright price target $10, Brookline raised price target to $22 from $19, Leerink Partners buy rating, William Blair buy rating , upcoming catalyst: 1) top line data phase 3 ENSURE trials end of 2026, company focuses on development of oral, small-molecule drugs aimed at treating chronic inflammatory and autoimmune disease 

✅ SNGX potential entry: $3.05 – $3.10  

🎯 Potential PT1: $3.50 – $3.80, 🎯 PT2: $4.00 – $4.50, 🎯 PT3: $4.60 – $5.20  

🚫 Potential Stop: Below $2.80 or 2%–5% or daily max risk per trade

Back to consolidation from recent high above 6.20, recently granted orphan drug designation to dusquetide, active ingredient for Behcet's disease, provides 7 years of U.S market exclusivity if approved, upcoming catalyst:  ongoing enrollment in phase 3 trial for HyBryte, company specializing in the development and commercialization of therapies for rare and underserved diseases,  Zacks Small-cap price target $35, Alliance Global Partners price target $6, 

 ✅ EDBL potential entry: $1.78 – $1.81
🎯 Potential PT1: $2.00 – $2.50, 🎯 PT2: $2.60 – $2.90, 🎯 PT3: $3.00 – $3.60
🚫 Potential Stop: Below $1.75 or 2%–5% or daily max risk per trade
Back to near 52wk low from recent high, recently expanded Pickle Party line through new retail placements, small float, recently announced its Kick, sports nutrition won 2025 Mindful Award Sports Nutrition "Product of the Year", which launched on $AMZN , also announced expansion of retail footprint across Northeast, company focused on growing organic herbs, lettuces and plant-based protein products using innovative greenhouse, hydroponic and vertical farming methods, 

 ✅ BMGL potential entry: $1.95 – $2.00
🎯 Potential PT1: $2.40 – $2.80, 🎯 PT2: $3.00 – $3.50, 🎯 PT3: $3.56 – $3.90
🚫 Potential Stop: Below $1.80 or 2%–5% or daily max risk per trade 

Back to support from recent high, small float, recently entered to purchase up to 10,000 $BTC up to $1 B via stock deal, , recently announced its subsidiary has been awarded #375M contract to supply essential healthcare products in Asia-Pacific until 10/31/2029, previously announced to acquire Bethesda Medical, company specializing in medical services including orthopedic surgery, trauma and sports medicine, spine and neurosurgical procedures, minimally invasive techniques, diagnostic imaging, and rehab services. 

 ✅ EEIQ potential entry: $0.54 – $0.59
🎯 Potential PT1: $0.80 – $1.30, 🎯 PT2: $1.50 – $1.80, 🎯 PT3: $2.00 – $2.40
🚫 Potential Stop: Below $0.45 or 2%–5% or daily max risk per trade
📌 Note: EEIQ has until 9/1/2025 to regain Nasdaq compliance or seek another 180-day extension;  Near 52wk low from recent high above 1.50 on strong financial results, recent offering price $.73 per share, recently entered into key agreement with MSM Unify, company focuses on providing educational services for international students heading to U.S, Canada, and UK, has until 9/1/2025 to regain compliance or file for another 180-day extension, no approved reverse split at this time 

 ✅ OFAL potential entry: $1.54 – $1.59
🎯 Potential PT1: $1.80 – $2.40, 🎯 PT2: $2.50 – $2.80, 🎯 PT3: $3.00 – $3.50
🚫 Potential Stop: Below $1.20 or 2%–5% or daily max risk per trade 

Recent IPO, back to near support, now accepting crypto payments for architectural, AI solutions, recently entered LOI with NExt Investments to establish joint venture to develop Next-Generation Senior Care facility, also recently launched digital asset strategy to enhance senior housing development, , does have active mixed shelf, be mindful on next spike, company focusing on architectural and design services, serving both commercial and residential, primarily in Hong Kong, 

✅ HWH potential entry: $1.30 – $1.35  

🎯 Potential PT1: $1.50 – $1.85, 🎯 PT2: $2.00 – $2.70, 🎯 PT3: $3.00 – $3.50  

🚫 Potential Stop: Below $1.00 or 2%–5% or daily max risk per trade

Back to near support from recent high, recent 1/5 reverse split, small float, a lifestyle and consumer company, merging cafe, e-commerce and fintech/coaching, recently announced approval of a new AI patent aimed at reducing operating costs 

 ✅ KITT potential entry: $0.83 – $0.87  

🎯 Potential PT1: $1.00 – $1.40, 🎯 PT2: $1.60 – $1.90, 🎯 PT3: $2.00 – $2.50  

🚫 Potential Stop: Below $0.75 or 2%–5% or daily max risk per trade

 Near 52wk low, recently announced collaboration in subsea asset management, previously announced early closer of SeaTrepid International Acquisition, and completion in the Gulf of Mexico to perform Subsea Field Inspection utilizing flagship Underwater vehicle 

✅ KIDZ potential entry: $1.20 – $1.25
🎯 Potential PT1: $1.50 – $1.90, 🎯 PT2: $2.10 – $2.50, 🎯 PT3: $2.70 – $3.20
🚫 Potential Stop: Below $1.00 or 2%–5% or daily max risk per trade 

Another rinse and repeat, recently announced $SOL.X holdings over $11M, also partnership announcement with Everstake to launch branded validator on Solana, previously announced $400M equity deal to back Solana-based treasury strategy, previously announced to hire 2500 US based teachers over next 12 to 24 months, company is an AI-powered education technology company based in New York, offering online live courses for k-12 students in US and internationally, does have mixed shelf, be mindful on next big spike

  ✅ PLUG potential entry: $1.60 – $1.65
🎯 PT1: $1.85 – $2.30, 🎯 PT2: $2.50 – $2.80, 🎯 PT3: $3.00 – $3.40
🚫 Stop: Below $1.40 or 2%–5% or daily max risk per trade 

 Another rinse and repeat, previously announces contract from Southwire, a North American manufacturer of wire and cable, to implement a clean hydrogen ecosystem at the new distribution site in Dallas TX, recently announced launching sport pricing for green hydrogen, also recently announced $30 M federal investment tax credit transfer, company specializing in hydrogen fuel cell systems, aiming to replace conventional batteries in electric-powered equipment and vehicles, HC Wainwright price target $5, Craig-Hallum price target $3, Evercore ISI Group price target $4, Roth Capital price target 3.50, CFO Paul Middleton recently bought 350K shares average price $0.7154, DOES HAVE ACTIVE MIXED SHELF, be mindful on next big spike 

✅ ENVB potential entry: $1.12 – $1.17  

🎯 Potential PT1: $1.35 – $1.65, 🎯 PT2: $1.80 – $2.20, 🎯 PT3: $2.40 – $2.80  

🚫 Potential Stop: Below $1.00 or 2%–5% or daily max risk per trade  

 Small float, recently received 2nd US patent allowance for Innovative Non-Hallucinogenic Mescaline Derivatives in Mental Health Treatment, previously reported positive preclinical data, previously launched RFP solication process for PsyAI trademark, HC Wainwright price target $10, company focuses on developing novel neuroplastogenic small-molecule therapeutics aimed at treating mental health disorders such as depression, anxiety, and addiction, their proprietary discovery platform, Psybrary, has led to a robust portfolio of drug candidates targeting neuropsychiatric conditions, upcoming catalyst: 1) IND filing for EB-003, lead candidate for the treatment of depressive and anxiety disorder, 2nd of 2025, 

 ✅ TMDE potential entry: $0.77 – $0.82
🎯 PT1: $0.95 – $1.30, 🎯 PT2: $1.50 – $1.80, 🎯 PT3: $2.00 – $2.60
🚫 Stop: Below $0.70 or 2%–5% or daily max risk per trade 

Back to support from recent high above 4.35, small float, recently announced partnership with Double Corporate for Green Bioenergy Expansion, previopusly announced expansion into oil waste collection, company specializes in the supply and marketing of marine gas oil and marine fuel oil based in Malaysia and Singapore,, also offers ship management services and vessels chartering. recent IPO 

 ✅ WBUY potential entry: $2.85 – $2.91
🎯 Potential PT1: $3.30 – $3.70, 🎯 PT2: $4.00 – $4.45, 🎯 PT3: $4.65 – $5.20
🚫 Potential Stop: Below $2.70 or 2%–5% or daily max risk per trade 

Back to support from recent high above 6 , recent offering at $3.65/share, recently announced partnerships with Victory Securities to pioneer stablecoin in E-Commerce and travel, recently launched AI Travel Assistant device, collaborated with China Tourism Giant to bring 20,000 travelers to China annually, company recognized as fastest-growing company in Asia-Pacific, company focuses on e-commerce and travel platform 

✅ APM potential entry: $1.20 – $1.25
🎯 Potential PT1: $1.50 – $1.80, 🎯 PT2: $2.00 – $2.40, 🎯 PT3: $2.60 – $2.90
🚫 Potential Stop: Below $1.00 or 2%–5% or daily max risk per trade 

 Recently announced NASDAQ compliance, recently announced merger with DiamiR Bioscience, aiming to advance brain health solutions, expected to close Q4 2025, recent offering at $2/share from recent high above $7, company focuses on targeting disease with unmet medical needs in oncology and infectious diseases. 

✅ SCNX potential entry: $1.10 – $1.15  

🎯 Potential PT1: $1.30 – $1.80, 🎯 PT2: $2.05 – $2.50, 🎯 PT3: $2.60 – $2.90  

🚫 Potential Stop: Below $1.00 or 2%–5% or daily max risk per trade

Back to key support from recent offering at $1.20 /share, recently announced shipment of ARBLI, the first FDA-approved ready to use liquid losasrtan to tis distribution center, marking major commercialization milestones, Arbli is the first and only FDA-approved ready-to-use oral liquid losartan available in the United States, designed to treat hypertension in patients over six years old, reduce stroke risk in patients with hypertension and left ventricular hypertrophy, and treat diabetic nephropathy in certain patients with type 2 diabetes, upcoming catalyst: 1) commercially launch Arbli in the Q3 of 2025 

✅ VERO potential entry: $2.35 – $2.40  

🎯 Potential PT1: $2.60 – $2.90, 🎯 PT2: $3.10 – $3.45, 🎯 PT3: $3.55 – $4.20  

🚫 Potential Stop: Below $2.20 or 2%–5% or daily max risk per trade

Another rinse and repeat, small float,  recent 13D filing shows Madryn Asset Management acquires 85.5% stake, recently entered unit purchase agreement with $META robotics and Mhg, also recently announced to sell hair transplant business to Meta Healthcare in $20m all cash deal, company focuses in minimally invasive and non-invasive aesthetic and hair-restoration devices

✅ APDN potential entry: $3.85 – $3.90  

🎯 Potential PT1: $4.20 – $4.80, 🎯 PT2: $5.05 – $5.50, 🎯 PT3: $5.70 – $6.20  

🚫 Potential Stop: Below $3.80 or 2%–5% or daily max risk per trade

 Near 52wk low, ultra small float <1m, recently secured $600K follow-on order for LineaDNA in Cancer Diagnostics, company specializing in enzymatic, cell-free synthetic DNA production 

✅ TLRY potential entry: $1.09 – $1.14  

🎯 Potential PT1: $1.40 – $1.80, 🎯 PT2: $2.00 – $2.40, 🎯 PT3: $2.50 – $2.85  

🚫 Potential Stop: Below $1.00 or 2%–5% or daily max risk per trade

 Back to near key support from recent high, Trump administration previously announced considering reclassifying cannabis from schedule 1 to schedule III, company operates in both the cannabis industry and consumer packaged goods, including beverage alcohol and CBD products, serving both medical and adult-use markets 

 ✅ NRXS potential entry: $2.35 – $2.40
🎯 PT1: $2.65 – $2.90, 🎯 PT2: $3.10 – $3.50, 🎯 PT3: $3.60 – $4.20
🚫 Stop: Below $2.20 or 2%–5% or daily max risk per trade 

 Previous Offering price 3.25, recently received Fda clearance for IB stim for treatment of pediatric FAP associated with functions dyspepsia and FD related nausea symptoms, previously announced Molina Healthcare coverage for PENFS Therapy IB Stim, FDA cleared for treating abdominal pain in IBS adolescents, Craig-Hallum buy rating price target $7 

 ✅ PEPG potential entry: $1.25 – $1.30
🎯 PT1: $1.50 – $1.80, 🎯 PT2: $2.00 – $2.50, 🎯 PT3: $2.60 – $3.20
🚫 Stop: Below $1.00 or 2%–5% or daily max risk per trade 

 Previously announced voluntarily pausing phase 2 CONNECT2-EDO51 study until company can review results from the 10mg/kg cohort, which is expected Q3 2025, HC Wainwright price target $14, Stifel Nicolaus buy rating on promising advances in DMD (Duchenne muscular dystrophy and DM1 (Myotonic dystrophy type 1) programs, DMD company focusing on developing next-generation oligonucleotide therapeutics to treat severe neuromuscular and neurological diseases 

 ✅ GFAI potential entry: $1.10 - $1.15
🎯 PT1: $1.40 - $1.80, 🎯 PT2: $2.00 - $2.50, 🎯 PT3: $2.75 - $3.50
🚫 Stop: Below $1.00 or 2%-5% or daily max risk per trade 

 Recently launched Smart Solutions in Thailand, also launched DVGO, an AI Travel planning tool powered by specialized AI agents in the United States, previously secured three-year renewal with Thailand's Government Saving Bank, D. Boral Capital price target 4.50, company is a global provider of integrated security solutions, specializing in both traditional security services and advanced AI and robotics technologies, offering services across regions throughout Asia 

 ✅ BITF potential entry: $1.20 - $1.25
🎯 PT1: $1.40 - $1.80, 🎯 PT2: $2.00 - $2.50, 🎯 PT3: $2.60 - $3.20
🚫 Stop: Below $1.00 or 2%-5% or daily max risk per trade 

 Recently announced partnership with T5 Data Centers to boost AI Development in Pennsylvania, Clear Street price target $6, Northland Securities price target $3.25, HC Wainwright price target $3.50, Alliance Global Partners buy rating price target $3.25, company specializes in mining $BTC using its own infrastructure including data centers and energy assets 

 ✅ MWYN potential entry: $0.95 - $1.00
🎯 PT1: $1.25 - $1.65, 🎯 PT2: $1.80 - $2.20, 🎯 PT3: $2.40 - $3.00
🚫 Stop: Below $0.80 or 2%-5% or daily max risk per trade 

Near 52wk low from recent high above 10 , recently IPO at $4 per share, back to key support, small float, Nevada-based company specializing in sourcing and distributing Asian food, as well as supplying kitchen cabinets and other home improvement products  

 SCNX potential entry: $2.15 - $2.20
🎯 PT1: $2.50 - $2.90, 🎯 PT2: $3.05 - $3.50, 🎯 PT3: $3.60 - $3.90
🚫 Stop: Below $2.00 or 2%-5% or daily max risk per trade 

Another rinse and repeat from previous swing below 1.0, back to support from recent high, announces shipment of ARBLI, the first FDA-approved ready to use liquid losasrtan to its distribution  center, marking major commercialization milestones, Arbli is the first and only FDA-approved ready-to-use oral liquid losartan available in the United States, designed to treat hypertension in patients over six years old, reduce stroke risk in patients with hypertension and left ventricular hypertrophy, and treat diabetic nephropathy in certain patients with type 2 diabetes, upcoming catalyst: 1) commercially launch Arbli in the Q3 of 2025, DOES have mixed shelf, be mindful on next big spike 

 ✅ BTBT potential entry: $2.97 - $3.03
🎯 PT1: $3.30 - $3.65, 🎯 PT2: $3.80 - $4.30, 🎯 PT3: $4.50 - $5.00
🚫 Stop: Below $3.00 or 2%-5% or daily max risk per trade 

Another rinse and repeat, recent offering price $3.06 share, recently announced has purchased approximately 19,683 $ETH.X , holding a total of  120,306, previously announced it rebranded its high-performance computing business as WhiteFiber, which recently filed for IPO under symbol $WYFI, Noble Financial buy rating, HC Wainwright Buy rating price target $7, CEO  Samir Tabar and Director Brock Pierce recently purchased shares (~750,000 and 500,000, respectively) ~ $2/share 

  ✅ SOAR potential entry: $1.31 - $1.36
🎯 PT1: $1.50 - $1.85, 🎯 PT2: $2.00 - $2.40, 🎯 PT3: $2.50 - $2.75
🚫 Stop: Below $1.15 or 2%-5% or daily max risk per trade 

 Near 52wk low from recent high, small float, recently announced merger with M2i Global, recently announced new Aircraft Leasing Program to boost revenue, company is an aviation-tech focused, offering a suite of services including fractional aircraft ownership, aircraft management, charters, jet cards, and a cloud-based platform (Vaunt) for travel bookings and scheduling, does have mixed shelf, be mindful on next big spike 

✅ HOTH potential entry: $1.13 - $1.17  

🎯 Potential PT1: $1.40 - $1.80, 🎯 PT2: $2.00 - $2.45, 🎯 PT3: $2.65 - $3.00  

🚫 Potential Stop: Below $1.00 or 2%-5% or daily max risk per trade

Recently entered joint venture with $SILO Pharma to commercialize VA-invented obesity Drug, expanded phase II clinical trial for HT-001, topical gel treating skin toxicities, across Europe in collaboration with ICON, recent data demonstrated significant reduction in tumor growth, announced patent to develop anti-obesity treatments with US Depart. Of Veterans Affairs, also previously purchased up to $1M of $BTC.X as treasury reverse asset, upcoming catalysts: 1) IND filing for HT-KIT, which recently announced positive data, suppressing tumor growth in preclinical models, expected to submit early 2026, D. Boral capital price target $5, HC Wainwright price target $4 

 ✅SILO potential entry: $0.62 - $0.67  

🎯 Potential PT1: $0.80 - $1.20, 🎯 PT2: $1.40 - $1.75, 🎯 PT3: $2.00 - $2.30  

🚫 Potential Stop: Below $0.45 or 2%-5% or daily max risk per trade

Small float, back to near 52wk low recent offering at $.60 share, recently launched cryptocurrency advisory board, recently acquired digital assets from MAVS holdings, have until 12/24/25 to regain Nasdaq compliance by bringing price above $1 for 10 consecutive days, recently partnered with $HOTH for obesity treatment, upcoming catalyst: 1) preclinical data on SPC-15, intranasal therapy (5-HT4 receptor agonist) aimed at PTSD and anxiety, leveraging a fast-acting nose-to-brain delivery mechanism in Q3, 

✅ NUVB potential entry: $2.30 – $2.35
🎯 Potential PT1: $2.70 – $3.30, 🎯 PT2: $3.50 – $3.80, 🎯 PT3: $4.00 – $4.50
🚫 Potential Stop: Below $2.00 or 2%–5% or daily max risk per trade 

RBC Capital buy rating price target $6,, HC Wainwright buy rating price target $10, TD Cowen buy rating, Citizens JMP buy rating, Wedbush buy rating price target $5, JMP Securities price target $6, FDA recently approved Ibtrozi for  advanced ROS-1+ NSCLS (Non‑Small Cell Lung Cancer),  recent corporate presentation highlighting breakthroughs in lung cancer treatment, upcoming catalyst: new data on IBTROZI in advance ROS1-Positive non-small cell lunch cancer at the World Conference on 9/6-9/9 in Spain and at the European Society oncology Congress Meetings on 10/17-10/21 in Berlin, company focuses on developing precision 

 ✅ ACRS potential entry: $1.55 – $1.60
🎯 Potential PT1: $1.90 – $2.20, 🎯 PT2: $2.40 – $2.75, 🎯 PT3: $3.00 – $3.40
🚫 Potential Stop: Below $1.40 or 2%–5% or daily max risk per trade 

Recent positive data, achieved primary and secondary endpoints, from phase 2b trial of ITK/JAK3 in atopic dermatitis (AD) patients, upcoming catalysts: 1) phase 1b data  end of 2025 for investigational bispecific anti-TSLP/IL-4R antibody ATI-052, 2) top line early 2026, followed by top line results from phase 1b portion 2nd half 2026,  3) results for phase 2 trial Anti-TSLP monoclonal antibody Bosakitug in patients with mod to severe AD 2nd half of 2026, Wedbush buy rating price target $8, HC Wainwright buy rating price target $16, Scotiabank price target $9, Piper Sandler buy rating 

 ✅ OPAD potential entry: $0.95 – $1.01
🎯 Potential PT1: $1.20 – $1.50, 🎯 PT2: $1.60 – $1.80, 🎯 PT3: $2.00 – $2.50
🚫 Potential Stop: Below $0.90 or 2%–5% or daily max risk per trade 

 Near 52wk low, recently sold 2.86M shares at $2.10 to institutional investor, company operates a technology-driven residential real estate platform in the US 

 ✅ SKYE potential entry: $3.50 – $3.56
🎯 Potential PT1: $3.80 – $4.30, 🎯 PT2: $4.50 – $5.00, 🎯 PT3: $5.20 – $5.75
🚫 Potential Stop: Below $3.40 or 2%–5% or daily max risk per trade 

Recently announced partnership with Arecor, company focuses on treating obesity, overweight, and metabolic disorders by developing novel molecules that modulate G protein-coupled receptors (GPCRs), JMP Securities price target $15, upcoming catalyst: 1) top line phase 2 data on nimacimab for obesity expected late Q3/4 2025 

 ✅  OPEN potential entry: $1.95–$2.01
🎯 Potential PT1: $2.30 – $2.60, 🎯 PT2: $2.80 – $3.30, 🎯 PT3: $4.00 – $4.30
🚫 Potential Stop: Below $1.80 or 2%–5% or daily max risk per trade 

Another rinse and repeat, recently announced partnership to bring Stargate to Europe,  REVERSE SPLIT  VOTING scheduled on 8/27/2025, voting was postponed because price pushed above $1 organically and not at risk for noncompliance, company focuses on buying and selling residential homes directly through online, EMJ Capital's Eric Jackson is the largest holding, targeting $82, JP Morgan buy rating 

 ✅ KIDZ potential entry: $1.20 – $1.30
🎯 Potential PT1: $1.50 – $1.90, 🎯 PT2: $2.10 – $2.50, 🎯 PT3: $2.70 – $3.20
🚫 Potential Stop: Below $1.00 or 2%–5% or daily max risk per trade 

Recently announced $SOL.X holdings over $11M, also partnership announcement with Everstake to launch branded validator on Solana, previously announced $400M equity deal to back Solana-based treasury strategy, previously announced to hire 2500 US based teachers over next 12 to 24 months, company is an AI-powered education technology company based in New York, offering online live courses for k-12 students in US and internationally, does have mixed shelf, be mindful on next big spike